AADAC Antibody (2E8) - Azide and BSA Free

ELISA: AADAC Antibody (2E8) [H00000013-M01] - AADAC Antibody (2E8) [H00000013-M01] - Detection limit for recombinant GST tagged AADAC is approximately 3ng/ml as a capture antibody.

• Reactivity: Hu, Mu, Rt, Pm
• Applications: WB, ELISA
• Clone: 2E8
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: Azide and BSA Free

AADAC Antibody (2E8) - Azide and BSA Free Summary

• Description: Quality control test: Antibody Reactive Against Recombinant Protein.
• Immunogen: AADAC (NP_001077, 201 a.a. ~ 300 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. QLLDDPDVKIKLKIQSLIYPALQPLDVDLPSYQENSNFLFLSKSLMVRFWSEYFTTDRSLEKAMLSRQHVPVESSHLFKFINWSSLLPERFIKGHVYNNP
• Specificity: arylacetamide deacetylase (esterase)
• Isotype: IgG2b Kappa
• Clonality: Monoclonal
• Host: Mouse
• Gene: AADAC
• Purity: IgG purified

Applications/Dilutions

• Dilutions:
  • ELISA
  • Western Blot 1:500
• Application Notes: Antibody reactivity against Recombinant Protein with GST tag on ELISA and WB. GST tag alone is used as a negative control.

Packaging, Storage & Formulations

• Storage: Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
• Buffer: In 1x PBS, pH 7.4
• Preservative: No Preservative
• Purity: IgG purified

Notes

This product is produced by and distributed for Abnova, a company based in Taiwan.

Alternate Names for AADAC Antibody (2E8) - Azide and BSA Free

• arylacetamide deacetylase (esterase)
• arylacetamide deacetylase
• CES5A1
• DACEC 3.1.1.3
• EC 3.1.1
• EC 3.1.1.79

Background

Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase, which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for AADAC Antibody (H00000013-M01)(5)

Publications using H00000013-M01

• Muta K, Fukami T, Nakajima M, Yokoi T. N-Glycosylation during translation is essential for human arylacetamide deacetylase enzyme activity. Biochem Pharmacol. 2013-10-03 [PMID: 24125761]
• Kobayashi Y, Fukami T, Higuchi R et al. Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. Biochem Pharmacol. 2012-08-23 [PMID: 22940574]
• Shimizu M, Fukami T, Kobayashi Y et al. A Novel Polymorphic Allele of Human Arylacetamide Deacetylase Leads to Diminished Enzyme Activity. Drug Metab Dispos. 2012-03-13 [PMID: 22415931]
• Kobayashi Y, Fukami T, Nakajima A et al. Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. Drug Metab Dispos. 2011-12-29 [PMID: 22207054]
• Watanabe A, Fukami T, Nakajima M et al. Human Arylacetamide Deacetylase Is A Principal Enzyme in Flutamide Hydrolysis. Drug Metab Dispos. 2009-04-01 [PMID: 19339378]

Bioinformatics

• Gene Symbol: AADAC
• Entrez:
  • 13(Human)
• OMIM:
  • 600338(Human)
• Uniprot:
  • NP_001077(Human)